Skip to content

Search

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years

Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia

This study provides a quantitative estimate of the total burden of invasive pneumococcal disease preventable by vaccination programs in Australia

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers

One dose of MenACWY-TT boosts protection against MenC in primed children, is safe and extends protection against MenA, MenW and MenY

Postvaccination Febrile Seizure Severity and Outcome

Vaccine-proximate febrile seizures accounted for a small proportion of all febrile seizures hospital presentations

Mandatory vaccination and no fault vaccine injury compensation schemes: An identification of country-level policies

Countries that mandate childhood vaccination without providing no fault compensation schemes could be seen as abrogating the social contract

The politics of picking: Selective vaccinators and population-level policy

Public health systems face tensions between individuals and the collective. Parents who selectively vaccinate demonstrate this tension

Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys

Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086

Assessment of the persistence of bactericidal antibodies up to 4 years after a three-dose schedule of bivalent rLP2086

The safety of maternal immunization

Existing evidence supporting the safety of vaccination during pregnancy should be used to reassure pregnant women and improve vaccine uptake in pregnancy